A5059376308- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Macular Surgery
- Ophthalmology and Visual Impairment Studies
- Cerebral Venous Sinus Thrombosis
- Intraocular Surgery and Lenses
- Optical Coherence Tomography Applications
- Diabetes Management and Research
- Laser Applications in Dentistry and Medicine
- Angiogenesis and VEGF in Cancer
- Ocular Surface and Contact Lens
- Ocular Infections and Treatments
- Delphi Technique in Research
- Genetics, Bioinformatics, and Biomedical Research
- Facial Rejuvenation and Surgery Techniques
- Ocular and Laser Science Research
- Lipid Membrane Structure and Behavior
- Ocular Disorders and Treatments
- Bariatric Surgery and Outcomes
- Machine Learning in Bioinformatics
- Traumatic Ocular and Foreign Body Injuries
- Mobile Health and mHealth Applications
Jaeb Center for Health Research
2016-2025
University of Pittsburgh
2025
Regeneron (United States)
2024
Retina Associates of Florida
2023
Research Network (United States)
2008-2016
SAS Institute (United States)
2016
Johns Hopkins University
2014-2016
Johns Hopkins Medicine
2014
University of Illinois Chicago
2014
Resurrection Medical Center
2012
The relative efficacy and safety of intravitreous aflibercept, bevacizumab, ranibizumab in the treatment diabetic macular edema are unknown.
Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage retina, resulting in peripheral vision or worsening macular edema (DME).To evaluate noninferiority of intravitreous ranibizumab compared with acuity outcomes patients retinopathy.Randomized clinical trial conducted at 55 US sites among 305 adults retinopathy enrolled between February and December 2012 (mean age, 52 years; 44% female; 52%...
Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed.To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years PDR.Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial evaluated 394 study PDR enrolled February December 2012. Analysis began in January 2018.Eyes were randomly assigned to receive (n = 191)...
Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks anti-vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment.To assess DME persisting at least after randomization treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab.Post hoc analyses a clinical trial, the DRCR.net Protocol T among 546 660 participants (82.7%) meeting inclusion criteria for this investigation.Six monthly intravitreous...
Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). The best approach to patients CI-DME and good (20/25 better) is unknown.To compare vision loss at 2 years among eyes initially managed aflibercept, laser photocoagulation, observation.Randomized clinical trial conducted 91 US Canadian sites 702 adults type 1...
Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF alone.To compare ranibizumab alone with plus dexamethasone implant DME.Phase 2 multicenter randomized clinical trial conducted at 40 US sites 129 from 116 adults diabetes between February 2014 and December 2016. Eyes had DME,...
The prevalence of persistent diabetic macular edema (DME) after months anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown.
<h3>Importance</h3> Anti–vascular endothelial growth factor (VEGF) medicines have revolutionized diabetic macular edema (DME) treatment. A recent randomized clinical trial comparing anti-VEGF agents for patients with decreased vision from DME found that at 1 year aflibercept (2.0 mg) achieved better visual outcomes than repackaged (compounded) bevacizumab (1.25 or ranibizumab (0.3 mg); the worse starting vision, greater treatment benefit aflibercept. However, and ranibizumab, respectively,...
The role of anti-vascular endothelial growth factor injections for the management nonproliferative diabetic retinopathy (NPDR) without center-involved macular edema (CI-DME) has not been clearly established.To determine efficacy intravitreous aflibercept compared with sham treatment in preventing potentially vision-threatening complications eyes moderate to severe NPDR.Data this study were collected between January 15, 2016, and May 28, 2020, from ongoing DRCR Retina Network Protocol W...
<h3>Objective</h3> To compare 2 laser photocoagulation techniques for treatment of diabetic macular edema: the modified Early Treatment Diabetic Retinopathy Study (ETDRS) direct/grid technique and a potentially milder (but more extensive) mild grid (MMG) in which microaneurysms are not treated directly small burns placed throughout macula, whether or edema is present. <h3>Methods</h3> Two hundred sixty-three subjects (mean age, 59 years) with previously untreated were randomly assigned to...
Purpose.: To evaluate macular thickness in people with diabetes but minimal or no retinopathy using Heidelberg Spectralis optical coherence tomography (OCT). Methods.: In a multicenter, cross-sectional study of mean retinal thickness, on OCT the nine standard subfields, spanning zone 6-mm diameter, center point, and total volume were evaluated. Central subfield (CSF) was evaluated for association demographic clinical factors. Stratus scans also performed each participant. Results.: The...
Moderate to substantial agreement between Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field imaging and ultrawide-field (UWF) has been suggested in single-center studies. Comparing images obtained by multiple centers could increase confidence that UWF can be used reliably place of ETDRS future clinical trials.To compare diabetic retinopathy (DR) severity from modified imaging.This preplanned, cross-sectional analysis included using the Clinical Research Network acquisition protocol...
Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents.To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment DME.Preplanned secondary analysis of data from a comparative effectiveness trial center-involved DME was conducted 650 participants receiving ranibizumab. Retinopathy worsening were...
In Brief Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. Methods: Three hundred forty-five with a visual acuity 20/320 better, center-involved laser, retinopathy prompt photocoagulation were randomly assigned to sham (n = 123), 0.5-mg 113) at baseline 4 weeks, 4-mg weeks 109). Treatment was investigator discretion from 14 56 weeks. Results: Mean changes (±SD)...